Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

TAK-279 effectively reduces psoriasis symptoms and is safe.

In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.

In this study, conditional deletion of BRD4 in OX40-expressing cells of mice led to alopecia, dermatitis, and loss of hair follicle stem cell function, revealing BRD4's role in skin inflammation and stem cell regulation.

This case report documents the first use of bimekizumab as monotherapy for dissecting cellulitis of the scalp, where a 27-year-old man experienced significant symptom relief without adverse effects after failing standard treatments.

This case report presents the first known instance of bimekizumab improving psoriatic scarring alopecia, suggesting potential benefits of dual IL-17A/IL-17F blockade for this rare and challenging condition, warranting further investigation.

This study identified specific genes upregulated in skin γδ T cells involved in alopecia areata, with findings suggesting these cells contribute to disease pathogenesis through inflammatory and Th1 response mechanisms in mouse and possibly human skin.

This narrative review explored the complex interconnections between psoriasis and other dermatological conditions like vitiligo, alopecia areata, and atopic dermatitis, highlighting shared immune dysfunctions that complicate diagnosis and treatment, with implications for research and holistic patient care.

Hair follicles are crucial for maintaining skin barrier function.

This literature review explores the role of biomarkers in personalized medicine for various dermatological conditions like Hidradenitis Suppurativa, Psoriasis, and Atopic Dermatitis, highlighting how they guide targeted therapies and the limitations of current markers in specificity, as reported by the authors.

This study reviews current evidence on the role of ILC3s in the skin, highlighting their potential involvement in responding to microbiome changes such as those associated with acne and suggesting gaps in understanding their mechanisms.

This review discussed the cutaneous manifestations of APECED, highlighting chronic mucocutaneous candidiasis, alopecia areata, and vitiligo, while emphasizing the importance of early detection and monitoring for accurate diagnosis and patient care in various populations.

This review concluded that interleukin-17 is involved in the development of female-pattern baldness, suggesting a potential inflammatory role in the condition’s underlying causes.

This study found that overexpression of miR-1246 in peripheral CD4+ T cells can reduce markers associated with inflammation and T cell activation in severe active alopecia areata, suggesting potential therapeutic benefits.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

In a Phase II trial, Cox and colleagues reported that anti-IL17A therapy was well tolerated and led to a 64% reduction in wound size for venous leg ulcers unresponsive to standard treatments, although further validation in a larger trial is needed.

This systematic review reported an association between specific interleukin gene polymorphisms (IL-17A, IL-18, IL17RA, and IL16) and alopecia areata, suggesting further genetic studies are needed to confirm the interleukins' role in the disorder's progression.

This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.

This paper discusses the evolving understanding of psoriasis pathogenesis with no new clinical findings; the authors highlight the role of T-cell plasticity and regulatory cells, calling for further clinical applications using single-cell technologies.

This review examines the role of autoinflammation and immune dysregulation in hidradenitis suppurativa, linking it to genetic factors and autoinflammatory syndromes, but highlights the need for further research to fully understand its pathogenic mechanisms.

In this study, researchers found that the rs3118470 mutation in the IL2RA gene significantly increases the risk of developing alopecia areata, and they emphasize the need for future research with larger, more diverse populations to validate these results.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This review reports that the unique tunnel structures in advanced hidradenitis suppurativa impair quality of life and resist biological therapy, with their formation involving complex cellular and molecular interactions, including microbial dysbiosis, all contributing to ongoing inflammation and scarring.

This review discusses the role of keratinocytes in hidradenitis suppurativa, highlighting their genetic and metabolic influences on disease progression without presenting new clinical results.

This study found that IL-1α and IL-7 secreted from keratinocytes in a genetically engineered mouse model can stimulate the expansion of γδT-cells, aiding in the proliferation of epidermal stem cells for wound healing.

In this study, researchers reported that IL-17C plays a key pro-inflammatory role in human skin diseases and may be a promising therapeutic target for inflammatory skin conditions.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

This article reviews the role of IL-17 in inflammatory skin disorders and highlights its potential therapeutic targeting in both neutrophilic and lymphocyte-mediated conditions, reporting no new experimental results.

This study explored IL-17D's role in skin biology and found no significant difference in disease progression between IL-17D KO and WT mice in skin inflammation models, but IL-17D did promote cell migration and modestly accelerated wound healing, suggesting it may influence tissue repair processes.

This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.